<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03176979</url>
  </required_header>
  <id_info>
    <org_study_id>1B-16-3</org_study_id>
    <secondary_id>NCI-2017-00778</secondary_id>
    <secondary_id>1B-16-3</secondary_id>
    <secondary_id>P30CA014089</secondary_id>
    <nct_id>NCT03176979</nct_id>
  </id_info>
  <brief_title>Contrast Enhanced Spectral Mammography With Digital Breast Tomosynthesis For Patients With Newly Diagnosed Breast Cancer</brief_title>
  <official_title>Emerging Tools in the Detection of Breast Cancer: Comparison of Contrast Enhanced Spectral Mammography With Digital Breast Tomosynthesis to Conventional Imaging Techniques Including Contrast Enhanced Magnetic Resonance Imaging and 2D Mammography With or Without Targeted Ultrasound</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies how well contrast enhanced spectral mammography works with&#xD;
      digital breast tomosynthesis in imaging patients with newly diagnosed breast cancer. Contrast&#xD;
      enhanced spectral mammography uses a special dye that is injected into the veins before&#xD;
      mammogram images are taken. Digital breast tomosynthesis uses multiple x-ray pictures to&#xD;
      produce a 3-dimensional rendering of the entire breast. Contrast enhanced spectral&#xD;
      mammography with digital breast tomosynthesis may highlight areas of concern within the&#xD;
      breast in more detail than a standard mammogram and improve the accuracy of tumor size.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To compare the index lesion size (the largest diameter) from each of the four readings&#xD;
      (standard of care 2 dimensional [D], magnetic resonance imaging [MRI], contrast enhanced&#xD;
      spectral mammography [CESM], 3D) to gold standard index lesion size from surgical pathology&#xD;
      (the largest diameter).&#xD;
&#xD;
      II. To document the additional ipsilateral and contralateral breast cancer lesions detected&#xD;
      by the MRI, CESM, and 3D readings listed above.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo a clinical breast examination and a diagnostic mammogram with or without&#xD;
      targeted breast ultrasound to the index cancer as part of their standard of care preoperative&#xD;
      work-up. As part of the research study, patients receive contrast agent intravenously (IV)&#xD;
      and then undergo a CESM with digital breast tomosynthesis (DBT) over 30 minutes. Patients&#xD;
      also receive a contrast agent, gadolinium, IV and undergo bilateral breast contrast enhanced&#xD;
      (CE)-MRI over 10 minutes.&#xD;
&#xD;
      After completion of study, patients are followed up within 24-96 hours.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 21, 2017</start_date>
  <completion_date type="Actual">July 8, 2021</completion_date>
  <primary_completion_date type="Actual">July 8, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Index lesion size using the largest diameter</measure>
    <time_frame>Baseline</time_frame>
    <description>Intra-class correlation will be used to assess the agreement of index lesion size from each imaging reading to the gold standard (histopathology at surgery). Bland-Altman plot will be used to illustrate the pattern of difference between each reading and the gold standard.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>Diagnostic (CESM with DBT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo a clinical breast examination and a diagnostic mammogram with or without targeted breast ultrasound to the index cancer as part of their standard of care preoperative work-up. As part of the research study, patients receive contrast agent IV and then undergo a CESM with DBT over 30 minutes. Patients also receive a contrast agent, gadolinium, IV and undergo bilateral breast CE-MRI over 10 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Contrast Agent</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic (CESM with DBT)</arm_group_label>
    <other_name>Contrast</other_name>
    <other_name>Contrast Drugs</other_name>
    <other_name>contrast material</other_name>
    <other_name>Contrast Medium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Digital Tomosynthesis Mammography</intervention_name>
    <description>Undergo CESM with DBT</description>
    <arm_group_label>Diagnostic (CESM with DBT)</arm_group_label>
    <other_name>DBT</other_name>
    <other_name>Digital Breast Tomosynthesis</other_name>
    <other_name>Digital Tomosynthesis of the Breast</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Dual-Energy Contrast-Enhanced Digital Spectral Mammography</intervention_name>
    <description>Undergo CESM with DBT</description>
    <arm_group_label>Diagnostic (CESM with DBT)</arm_group_label>
    <other_name>Dual-Energy Contrast-Enhanced Digital Mammography (CEDM)</other_name>
    <other_name>Dual-Energy Contrast-Enhanced Digital Subtraction Mammography</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed breast cancer patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women with history of surgical, medical, or radiation therapy for breast cancer&#xD;
&#xD;
          -  Women with renal failure or insufficiency&#xD;
&#xD;
          -  Women with iodine contrast allergy&#xD;
&#xD;
          -  Women with gadolinium contrast allergy&#xD;
&#xD;
          -  Women who are pregnant, possibly pregnant, or lactating&#xD;
&#xD;
          -  Women undergoing neoadjuvant chemotherapy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Yamashita, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USC / Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 2, 2017</study_first_submitted>
  <study_first_submitted_qc>June 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2017</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

